Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

GNLX | Genelux Corp

Healthcare | Biotechnology | USA | NASD
Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.58 Insider Own30.00% Shs Outstand24.55M Perf Week-18.16%
Market Cap580.30M Forward P/E- EPS next Y-0.84 Insider Trans-3.90% Shs Float18.10M Perf Month0.00%
Income-14.77M PEG- EPS next Q-0.18 Inst Own1.92% Short Float / Ratio0.92% / 0.94 Perf Quarter-30.31%
Sales11.24M P/S51.63 EPS this Y-151.76% Inst Trans- Short Interest0.17M Perf Half Y-26.06%
Book/sh0.86 P/B26.07 EPS next Y21.81% ROA-72.95% Target Price31.50 Perf Year-
Cash/sh1.05 P/C21.38 EPS next 5Y- ROE- 52W Range5.35 - 40.98 Perf YTD264.88%
Dividend- P/FCF- EPS past 5Y- ROI-62.90% 52W High-45.24% Beta-
Dividend %- Quick Ratio3.64 Sales past 5Y0.00% Gross Margin90.83% 52W Low319.44% ATR2.82
Employees15 Current Ratio3.64 Sales Q/Q- Oper. Margin-76.59% RSI (14)43.59 Volatility12.84% 11.03%
OptionableNo Debt/Eq0.08 EPS Q/Q-88.53% Profit Margin-131.44% Rel Volume1.43 Prev Close24.97
ShortableYes LT Debt/Eq0.06 EarningsAug 14 BMO Payout- Avg Volume177.97K Price22.44
Recom2.00 SMA20-8.23% SMA50-7.10% SMA200-6.09% Volume255,372 Change-10.13%
Date Action Analyst Rating Change Price Target Change
Sep-12-23Initiated Maxim Group Buy $40
Feb-15-23Initiated The Benchmark Company Speculative Buy $10
Sep-19-23 03:01PM
Director John Thomas Sells 6667 Shares of Genelux Corp (GNLX)
(GuruFocus.com) +8.04%
Sep-15-23 03:03PM
Director John Smither Sells 900 Shares of Genelux Corp (GNLX)
(GuruFocus.com)
Sep-14-23 01:21PM
10% Owner Aladar Szalay Sells 52,616 Shares of Genelux Corp (GNLX)
(GuruFocus.com)
07:00AM
Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-07-23 04:01PM
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference
(GlobeNewswire)
07:00AM Loading…
Aug-28-23 07:00AM
Genelux Corporation Announces New Chief Financial Officer
(GlobeNewswire) +11.01%
Aug-14-23 07:00AM
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
(GlobeNewswire)
Aug-02-23 04:00PM
Genelux Corporation to Participate in Fireside Chat at BTIGs Virtual Biotechnology Conference 2023
(GlobeNewswire)
01:08AM
10 Recent IPOs in 2023 to Consider
(Insider Monkey)
Jul-28-23 10:54AM
Why Shares of Genelux Climbed This Week
(Motley Fool) -9.38%
Jul-20-23 04:45PM
Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires
(GlobeNewswire) -10.85%
Jul-10-23 07:00AM
Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology
(GlobeNewswire)
Jun-29-23 07:00AM
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics, LLC
(GlobeNewswire)
Jun-22-23 07:00AM
Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023
(GlobeNewswire) -7.05%
Jun-12-23 07:00AM
Genelux Corporation Announces $18 Million Private Placement
(GlobeNewswire) +7.58%
05:19PM Loading…
Jun-01-23 05:19PM
Why Shares of Genelux Corporation Jumped This Week
(Motley Fool) +6.62%
May-25-23 04:01PM
Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology
(GlobeNewswire) +6.62%
May-15-23 07:00AM
Genelux Corporation Announces $33 Million Private Placement
(GlobeNewswire) -9.06%
Mar-23-23 07:00AM
Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023
(GlobeNewswire)
Jan-25-23 09:00PM
Genelux Corporation Announces Pricing of Initial Public Offering
(GlobeNewswire)
Genelux Corp. manufactures and markets drugs and virus strains solutions. It provides drug research, development, and clinical trial services for the healthcare industry. The company was founded by Aladar Szalay in 2001 and is headquartered in Westlake Village, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szalay Aladar10% OwnerSep 22Sale27.339,042247,1231,572,986Sep 25 06:30 PM
Szalay Aladar10% OwnerSep 21Sale28.467,549214,8781,582,028Sep 25 06:30 PM
Ryder SeanGeneral CounselSep 20Option Exercise6.0010,00060,00010,572Sep 21 04:30 PM
Yu YongVP, Clinical Trial OperationsSep 20Option Exercise6.006,00036,000112,135Sep 21 04:35 PM
Ryder SeanGeneral CounselSep 20Sale30.0010,000300,000572Sep 21 04:30 PM
Yu YongVP, Clinical Trial OperationsSep 20Sale27.966,000167,786106,135Sep 21 04:35 PM
Szalay Aladar10% OwnerSep 19Sale26.4532,167850,9420Sep 20 04:48 PM
Szalay Aladar10% OwnerSep 18Sale23.2930,292705,6495,000Sep 20 04:48 PM
Thomas JohnDirectorSep 18Sale24.993,33483,317475,793Sep 18 08:12 PM
Yu YongVP, Clinical Trial OperationsSep 15Option Exercise6.0010,40062,400116,535Sep 18 08:13 PM
Yu YongVP, Clinical Trial OperationsSep 15Sale21.8910,400227,630106,135Sep 18 08:13 PM
Thomas JohnDirectorSep 15Sale21.903,33372,996479,127Sep 18 08:12 PM
Szalay Aladar10% OwnerSep 14Sale22.0725,276557,80635,292Sep 15 04:19 PM
Yu YongVP, Clinical Trial OperationsSep 13Sale21.1429,800629,927106,135Sep 15 08:06 PM
Szalay Aladar10% OwnerSep 13Sale21.4419,032408,09360,568Sep 15 04:19 PM
Smither John WDirectorSep 13Sale20.7890018,7026,920Sep 14 08:18 PM
Szalay Aladar10% OwnerSep 12Sale22.2620,265451,16779,600Sep 13 07:04 PM
Szalay Aladar10% OwnerSep 11Sale22.2232,351718,70299,865Sep 13 07:04 PM
Szalay Aladar10% OwnerSep 08Sale23.1724,831575,332132,216Sep 11 07:05 PM
Szalay Aladar10% OwnerSep 07Sale24.3712,446303,268157,047Sep 11 07:05 PM
Yu YongVP, Clinical Trial OperationsAug 30Sale24.7019,800489,060135,935Aug 30 07:22 PM
Zindrick ThomasPresident and CEOAug 18Sale23.738,349198,12214,651Aug 22 04:13 PM
Cappello JosephVP, Pharmaceutical DevelopmentAug 18Sale23.733,26577,4785,735Aug 22 04:15 PM
Yu YongVP, Clinical Trial OperationsAug 18Sale23.733,26577,478155,735Aug 22 04:14 PM
Samuelson DougChief Financial OfficerAug 18Sale23.731,29730,7782,303Aug 22 04:17 PM
Smalling RalphHead of RegulatoryAug 18Sale23.7393522,1882,065Aug 22 04:18 PM
Jewett CarolineHead of QualityAug 18Sale23.7351512,2211,135Aug 22 04:18 PM
Ryder SeanGeneral CounselAug 18Sale23.733287,783572Aug 22 04:16 PM
Zhang QianAssociate VP, ResearchJan 26Buy6.252001,250200Jan 31 03:42 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2023 FINVIZ.com. All Rights Reserved.